Angelini and Arvelle create neurology player with $960m merger
There’s a new player in the neurology and mental health drugs market after Italy’s Angelini Pharma merged with Switzerland’s Arvelle Therapeutics in a deal worth up to $960 million based around the anti-seizure drug cenobamate. Angelini is an international pharma company that is part of… Read More »Angelini and Arvelle create neurology player with $960m merger
